{"id":44356,"date":"2022-05-25T23:03:01","date_gmt":"2022-05-25T21:03:01","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/data-demonstrating-decisiondx-melanomas-ability-to-risk-stratify-patients-according-to-melanoma-specific-survival-to-be-shared-during-the-2022-asco-annual-meeting\/"},"modified":"2022-05-25T23:03:01","modified_gmt":"2022-05-25T21:03:01","slug":"data-demonstrating-decisiondx-melanomas-ability-to-risk-stratify-patients-according-to-melanoma-specific-survival-to-be-shared-during-the-2022-asco-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/data-demonstrating-decisiondx-melanomas-ability-to-risk-stratify-patients-according-to-melanoma-specific-survival-to-be-shared-during-the-2022-asco-annual-meeting\/","title":{"rendered":"Data Demonstrating DecisionDx\u00ae-Melanoma\u2019s Ability to Risk-Stratify Patients According to Melanoma-Specific Survival to be Shared during the 2022 ASCO Annual Meeting"},"content":{"rendered":"<div>\n<p>FRIENDSWOOD, Texas&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/search?q=%24CSTL&amp;src=ctag\" target=\"_blank\" rel=\"noopener\">$CSTL<\/a> <a href=\"https:\/\/twitter.com\/hashtag\/CSTL?src=hash\" target=\"_blank\" rel=\"noopener\">#CSTL<\/a>&#8211;Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that an abstract demonstrating the ability of the Company\u2019s DecisionDx\u00ae-Melanoma test to risk-stratify patients with cutaneous melanoma according to their survival likelihood will be available online during the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually and in Chicago, June 3-7, 2022.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220525005857\/en\/1467552\/5\/CastleLogo2Color.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220525005857\/en\/1467552\/21\/CastleLogo2Color.jpg\"><\/a><\/p>\n<p>\nDetails are as follows:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Abstract Title:<\/b> \u201cValidation of the 31-gene expression profile test to stratify melanoma-specific survival in an unselected, prospectively tested cohort of patients with stage IIB-III cutaneous melanoma\u201d\n<\/li>\n<li>\n<b>Abstract number: <\/b>e21538\n<\/li>\n<\/ul>\n<p>\n<b>About DecisionDx\u00ae-Melanoma<\/b>\n<\/p>\n<p>\nDecisionDx-Melanoma is a gene expression profile test that uses an individual patient\u2019s tumor biology to predict individual risk of cutaneous melanoma (CM) metastasis or recurrence, as well as the risk of sentinel lymph node positivity, independent of traditional staging factors, and has been studied in more than 6,300 patient samples. Using tissue from the primary melanoma, the test measures the expression of 31 genes. Additionally, Castle has an ongoing collaboration with the National Cancer Institute (NCI) to link DecisionDx-Melanoma testing data with data from the Surveillance, Epidemiology and End Results (SEER) Program\u2019s registries on CM cases. This collaboration has resulted in Castle\u2019s analysis of 5,226 samples (clinically tested through December 31, 2018) in a study to evaluate melanoma-specific survival and overall survival; in this study, patients tested with DecisionDx-Melanoma had better survival rates than untested patients, and the data suggested that DecisionDx-Melanoma can accurately risk-stratify for disease progression to aid in risk-aligned treatment plans for improved patient outcomes and survival. The test has been validated in four archival risk of recurrence studies of 901 patients and six prospective risk of recurrence studies including more than 1,600 patients. Additionally, impact on patient management plans for one of every two patients tested has been shown in five multi-center\/single-center studies including more than 800 patients. The consistent performance and accuracy demonstrated in these studies provides confidence in disease management plans that incorporate DecisionDx-Melanoma test results. To predict risk of recurrence and likelihood of sentinel lymph node positivity, the Company utilizes its proprietary algorithms, i31-ROR and i31-SLNB, to produce an Integrated Test Result. Through March 31, 2022, DecisionDx-Melanoma has been ordered 97,288 times for patients with cutaneous melanoma.\n<\/p>\n<p>\nMore information about the test and disease can be found at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.CastleTestInfo.com&amp;esheet=52731150&amp;newsitemid=20220525005857&amp;lan=en-US&amp;anchor=www.CastleTestInfo.com&amp;index=1&amp;md5=cd04f2e6b29f00add15ce8897439e39b\" rel=\"nofollow noopener\" shape=\"rect\">www.CastleTestInfo.com<\/a>.\n<\/p>\n<p>\n<b>About Castle Biosciences<\/b>\n<\/p>\n<p>\nCastle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.\n<\/p>\n<p>\nCastle\u2019s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett\u2019s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.CastleBiosciences.com&amp;esheet=52731150&amp;newsitemid=20220525005857&amp;lan=en-US&amp;anchor=www.CastleBiosciences.com&amp;index=2&amp;md5=6215c755caf03f15d8ed7c7891f05d79\" rel=\"nofollow noopener\" shape=\"rect\">www.CastleBiosciences.com<\/a> and connect with us on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fcastle-biosciences-inc-%2F&amp;esheet=52731150&amp;newsitemid=20220525005857&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=3&amp;md5=30f1be4b8265c98356a24ab03d3c7938\" rel=\"nofollow noopener\" shape=\"rect\">LinkedIn<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2Fcastlebiosciences%2F&amp;esheet=52731150&amp;newsitemid=20220525005857&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=6c7baa549c5c18050b5e0fd92441f088\" rel=\"nofollow noopener\" shape=\"rect\">Facebook<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fcastlebio%3Flang%3Den&amp;esheet=52731150&amp;newsitemid=20220525005857&amp;lan=en-US&amp;anchor=Twitter&amp;index=5&amp;md5=6045090a5872cfbb135ee2ac365c6dd9\" rel=\"nofollow noopener\" shape=\"rect\">Twitter<\/a> and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fcastlebiosciences%2F&amp;esheet=52731150&amp;newsitemid=20220525005857&amp;lan=en-US&amp;anchor=Instagram&amp;index=6&amp;md5=e0593ade76d0c7c747df13e1a90d7781\" rel=\"nofollow noopener\" shape=\"rect\">Instagram<\/a>.\n<\/p>\n<p>\nDecisionDx-Melanoma, DecisionDx-CM<i>Seq<\/i>, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UM<i>Seq<\/i>, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.\n<\/p>\n<p>\n<b>Forward-Looking Statements<\/b>\n<\/p>\n<p>\n<i>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the \u201csafe harbor\u201d created by those sections. These forward-looking statements include, but are not limited to, statements concerning <\/i><i>the ability of our DecisionDx\u00ae-Melanoma test to risk-stratify patients with cutaneous melanoma according to their survival likelihood. <\/i><i>The words \u201cpotential,\u201d \u201cmay,\u201d \u201ccan,\u201d \u201canticipates,\u201d \u201cbelieves\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation: subsequent study or trial results and findings may contradict earlier study or trial results and findings or may not support the results obtained in this study, including with respect to the discussion of <\/i><i>DecisionDx\u00ae-Melanoma<\/i><i> in this press release; actual application of our <\/i><i>DecisionDx\u00ae-Melanoma<\/i><i> test may not provide the aforementioned benefits to patients; and the risks set forth under the heading \u201cRisk Factors\u201d in our Quarterly Report on Form 10-Q for the three months ended March 31, 2022, and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law.<\/i>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Investor Contact:<\/b><br \/>Camilla Zuckero<br \/>\n<br \/><a target=\"_blank\" href=\"m&#97;&#x69;&#x6c;&#x74;o&#58;&#99;&#x7a;&#x75;c&#107;&#101;&#x72;&#x6f;&#64;c&#97;&#x73;&#x74;&#x6c;e&#98;&#x69;&#x6f;&#x73;c&#105;&#101;&#x6e;&#x63;e&#115;&#46;&#x63;&#x6f;m\" rel=\"nofollow noopener\" shape=\"rect\">&#x63;&#x7a;&#x75;&#x63;&#x6b;&#x65;&#x72;&#x6f;&#x40;&#x63;&#x61;&#x73;&#x74;&#x6c;&#x65;&#x62;&#x69;&#x6f;&#x73;&#x63;&#x69;&#x65;&#110;&#99;&#101;&#115;&#46;&#99;&#111;&#109;<\/a>\n<\/p>\n<p>\n<b>Media Contact:<\/b><br \/>Allison Marshall<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;i&#108;&#x74;&#111;&#x3a;a&#109;&#x61;r&#x73;&#x68;&#97;&#x6c;l&#64;&#x63;a&#x73;&#x74;&#108;&#x65;b&#105;&#x6f;&#115;&#x63;i&#101;&#x6e;c&#101;&#x73;&#46;&#x63;o&#109;\" rel=\"nofollow noopener\" shape=\"rect\">am&#97;&#114;&#115;&#x68;&#x61;&#x6c;&#x6c;&#x40;ca&#115;&#116;&#108;&#x65;&#x62;&#x69;&#x6f;&#x73;ci&#101;&#110;&#99;&#x65;&#x73;&#x2e;&#x63;&#x6f;m<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>FRIENDSWOOD, Texas&#8211;(BUSINESS WIRE)&#8211;$CSTL #CSTL&#8211;Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that an abstract demonstrating the ability of the Company\u2019s DecisionDx\u00ae-Melanoma test to risk-stratify patients with cutaneous melanoma according to their survival likelihood will be available online during the upcoming 2022 American Society of Clinical &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/data-demonstrating-decisiondx-melanomas-ability-to-risk-stratify-patients-according-to-melanoma-specific-survival-to-be-shared-during-the-2022-asco-annual-meeting\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44356","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Data Demonstrating DecisionDx\u00ae-Melanoma\u2019s Ability to Risk-Stratify Patients According to Melanoma-Specific Survival to be Shared during the 2022 ASCO Annual Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/data-demonstrating-decisiondx-melanomas-ability-to-risk-stratify-patients-according-to-melanoma-specific-survival-to-be-shared-during-the-2022-asco-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Data Demonstrating DecisionDx\u00ae-Melanoma\u2019s Ability to Risk-Stratify Patients According to Melanoma-Specific Survival to be Shared during the 2022 ASCO Annual Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"FRIENDSWOOD, Texas&#8211;(BUSINESS WIRE)&#8211;$CSTL #CSTL&#8211;Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that an abstract demonstrating the ability of the Company\u2019s DecisionDx\u00ae-Melanoma test to risk-stratify patients with cutaneous melanoma according to their survival likelihood will be available online during the upcoming 2022 American Society of Clinical ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/data-demonstrating-decisiondx-melanomas-ability-to-risk-stratify-patients-according-to-melanoma-specific-survival-to-be-shared-during-the-2022-asco-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-25T21:03:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220525005857\/en\/1467552\/21\/CastleLogo2Color.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/data-demonstrating-decisiondx-melanomas-ability-to-risk-stratify-patients-according-to-melanoma-specific-survival-to-be-shared-during-the-2022-asco-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/data-demonstrating-decisiondx-melanomas-ability-to-risk-stratify-patients-according-to-melanoma-specific-survival-to-be-shared-during-the-2022-asco-annual-meeting\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Data Demonstrating DecisionDx\u00ae-Melanoma\u2019s Ability to Risk-Stratify Patients According to Melanoma-Specific Survival to be Shared during the 2022 ASCO Annual Meeting\",\"datePublished\":\"2022-05-25T21:03:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/data-demonstrating-decisiondx-melanomas-ability-to-risk-stratify-patients-according-to-melanoma-specific-survival-to-be-shared-during-the-2022-asco-annual-meeting\\\/\"},\"wordCount\":845,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/data-demonstrating-decisiondx-melanomas-ability-to-risk-stratify-patients-according-to-melanoma-specific-survival-to-be-shared-during-the-2022-asco-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220525005857\\\/en\\\/1467552\\\/21\\\/CastleLogo2Color.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/data-demonstrating-decisiondx-melanomas-ability-to-risk-stratify-patients-according-to-melanoma-specific-survival-to-be-shared-during-the-2022-asco-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/data-demonstrating-decisiondx-melanomas-ability-to-risk-stratify-patients-according-to-melanoma-specific-survival-to-be-shared-during-the-2022-asco-annual-meeting\\\/\",\"name\":\"Data Demonstrating DecisionDx\u00ae-Melanoma\u2019s Ability to Risk-Stratify Patients According to Melanoma-Specific Survival to be Shared during the 2022 ASCO Annual Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/data-demonstrating-decisiondx-melanomas-ability-to-risk-stratify-patients-according-to-melanoma-specific-survival-to-be-shared-during-the-2022-asco-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/data-demonstrating-decisiondx-melanomas-ability-to-risk-stratify-patients-according-to-melanoma-specific-survival-to-be-shared-during-the-2022-asco-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220525005857\\\/en\\\/1467552\\\/21\\\/CastleLogo2Color.jpg\",\"datePublished\":\"2022-05-25T21:03:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/data-demonstrating-decisiondx-melanomas-ability-to-risk-stratify-patients-according-to-melanoma-specific-survival-to-be-shared-during-the-2022-asco-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/data-demonstrating-decisiondx-melanomas-ability-to-risk-stratify-patients-according-to-melanoma-specific-survival-to-be-shared-during-the-2022-asco-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/data-demonstrating-decisiondx-melanomas-ability-to-risk-stratify-patients-according-to-melanoma-specific-survival-to-be-shared-during-the-2022-asco-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220525005857\\\/en\\\/1467552\\\/21\\\/CastleLogo2Color.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220525005857\\\/en\\\/1467552\\\/21\\\/CastleLogo2Color.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/data-demonstrating-decisiondx-melanomas-ability-to-risk-stratify-patients-according-to-melanoma-specific-survival-to-be-shared-during-the-2022-asco-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Data Demonstrating DecisionDx\u00ae-Melanoma\u2019s Ability to Risk-Stratify Patients According to Melanoma-Specific Survival to be Shared during the 2022 ASCO Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Data Demonstrating DecisionDx\u00ae-Melanoma\u2019s Ability to Risk-Stratify Patients According to Melanoma-Specific Survival to be Shared during the 2022 ASCO Annual Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/data-demonstrating-decisiondx-melanomas-ability-to-risk-stratify-patients-according-to-melanoma-specific-survival-to-be-shared-during-the-2022-asco-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Data Demonstrating DecisionDx\u00ae-Melanoma\u2019s Ability to Risk-Stratify Patients According to Melanoma-Specific Survival to be Shared during the 2022 ASCO Annual Meeting - Pharma Trend","og_description":"FRIENDSWOOD, Texas&#8211;(BUSINESS WIRE)&#8211;$CSTL #CSTL&#8211;Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that an abstract demonstrating the ability of the Company\u2019s DecisionDx\u00ae-Melanoma test to risk-stratify patients with cutaneous melanoma according to their survival likelihood will be available online during the upcoming 2022 American Society of Clinical ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/data-demonstrating-decisiondx-melanomas-ability-to-risk-stratify-patients-according-to-melanoma-specific-survival-to-be-shared-during-the-2022-asco-annual-meeting\/","og_site_name":"Pharma Trend","article_published_time":"2022-05-25T21:03:01+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220525005857\/en\/1467552\/21\/CastleLogo2Color.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/data-demonstrating-decisiondx-melanomas-ability-to-risk-stratify-patients-according-to-melanoma-specific-survival-to-be-shared-during-the-2022-asco-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/data-demonstrating-decisiondx-melanomas-ability-to-risk-stratify-patients-according-to-melanoma-specific-survival-to-be-shared-during-the-2022-asco-annual-meeting\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Data Demonstrating DecisionDx\u00ae-Melanoma\u2019s Ability to Risk-Stratify Patients According to Melanoma-Specific Survival to be Shared during the 2022 ASCO Annual Meeting","datePublished":"2022-05-25T21:03:01+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/data-demonstrating-decisiondx-melanomas-ability-to-risk-stratify-patients-according-to-melanoma-specific-survival-to-be-shared-during-the-2022-asco-annual-meeting\/"},"wordCount":845,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/data-demonstrating-decisiondx-melanomas-ability-to-risk-stratify-patients-according-to-melanoma-specific-survival-to-be-shared-during-the-2022-asco-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220525005857\/en\/1467552\/21\/CastleLogo2Color.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/data-demonstrating-decisiondx-melanomas-ability-to-risk-stratify-patients-according-to-melanoma-specific-survival-to-be-shared-during-the-2022-asco-annual-meeting\/","url":"https:\/\/pharma-trend.com\/en\/data-demonstrating-decisiondx-melanomas-ability-to-risk-stratify-patients-according-to-melanoma-specific-survival-to-be-shared-during-the-2022-asco-annual-meeting\/","name":"Data Demonstrating DecisionDx\u00ae-Melanoma\u2019s Ability to Risk-Stratify Patients According to Melanoma-Specific Survival to be Shared during the 2022 ASCO Annual Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/data-demonstrating-decisiondx-melanomas-ability-to-risk-stratify-patients-according-to-melanoma-specific-survival-to-be-shared-during-the-2022-asco-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/data-demonstrating-decisiondx-melanomas-ability-to-risk-stratify-patients-according-to-melanoma-specific-survival-to-be-shared-during-the-2022-asco-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220525005857\/en\/1467552\/21\/CastleLogo2Color.jpg","datePublished":"2022-05-25T21:03:01+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/data-demonstrating-decisiondx-melanomas-ability-to-risk-stratify-patients-according-to-melanoma-specific-survival-to-be-shared-during-the-2022-asco-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/data-demonstrating-decisiondx-melanomas-ability-to-risk-stratify-patients-according-to-melanoma-specific-survival-to-be-shared-during-the-2022-asco-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/data-demonstrating-decisiondx-melanomas-ability-to-risk-stratify-patients-according-to-melanoma-specific-survival-to-be-shared-during-the-2022-asco-annual-meeting\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220525005857\/en\/1467552\/21\/CastleLogo2Color.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220525005857\/en\/1467552\/21\/CastleLogo2Color.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/data-demonstrating-decisiondx-melanomas-ability-to-risk-stratify-patients-according-to-melanoma-specific-survival-to-be-shared-during-the-2022-asco-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Data Demonstrating DecisionDx\u00ae-Melanoma\u2019s Ability to Risk-Stratify Patients According to Melanoma-Specific Survival to be Shared during the 2022 ASCO Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44356","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44356"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44356\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44356"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44356"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44356"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}